Quantum Genomics Société Anonyme Yönetim

Yönetim kriter kontrolleri 0/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Mathieu Bigois

İcra Kurulu Başkanı

n/a

Toplam tazminat

CEO maaş yüzdesi	n/a
CEO görev süresi	less than a year
CEO sahipliği	n/a
Yönetim ortalama görev süresi	Veri yok
Yönetim Kurulu ortalama görev süresi	2.4yrs

Son yönetim güncellemeleri

Recent updates

CEO

Mathieu Bigois

less than a year

Görev süresi

Mr. Mathieu Bigois serves as Chief Executive Officer & Chairman of the Board at Quantum Genomics Société Anonyme from 2024. Mr. Bigois serves as Investment Consultant at Ally Bridge Group. He started his c...

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Mathieu Bigois	CEO & Chairman of the Board	less than a year	Veri yok	Veri yok
George L. Bakris	Member of Scientific & Clinical Advisory Board	2.4yrs	Veri yok	Veri yok
Alexandre Persu	Member of Scientific & Clinical Advisory Board	no data	Veri yok	Veri yok
Keith Ferdinand	Member of Scientific & Clinical Advisory Board	8.8yrs	Veri yok	Veri yok
Gregory Lip	Member of Scientific & Clinical Advisory Board	2.4yrs	Veri yok	Veri yok
Atul Pathak	Member of Scientific & Clinical Advisory Board	2.4yrs	Veri yok	Veri yok
Pascal Ghoson	Director	less than a year	Veri yok	Veri yok
Laurent Narbonne	Director	less than a year	Veri yok	Veri yok

2.4yrs

Ortalama Görev Süresi

Deneyimli Yönetim Kurulu: ALQGC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 2.4 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Quantum Genomics Société Anonyme Yönetim

Yönetim kriter kontrolleri 0/4

Anahtar bilgiler

Son yönetim güncellemeleri

Less than half of directors are independent

Quantum Genomics Announces the Appointment of Its New Scientific Advisory Board

Quantum Genomics Appoints Sarah Merlen Boulenger as Head of Regulatory Affairs

No independent directors

Quantum Genomics Société Anonyme Announces Resignation of Jean-Paul Kress from the Board

Recent updates

New minor risk - Financial data availability

New major risk - Shareholder dilution

New major risk - Shareholder dilution

New major risk - Revenue and earnings growth

New major risk - Financial position

No longer forecast to breakeven

New major risk - Share price stability

Full year 2022 earnings: Revenues miss analyst expectations

Consensus EPS estimates fall from profit to €0.33 loss

Forecast breakeven date pushed back to 2024

Less than half of directors are independent

Price target decreased to €9.76

Quantum Genomics Announces Lack of Significant Efficacy for Firibastat in Their Phase III Study, Fresh and Is Redirecting to New Developments

Forecast breakeven date pushed back to 2023

First half 2022 earnings released: EPS: €0 (vs €0.23 loss in 1H 2021)

Forecast breakeven date pushed back to 2023

Consensus forecasts updated

Quantum Genomics Announces the Appointment of Its New Scientific Advisory Board

Quantum Genomics Announces the End of Patient Recruitment for its Phase III Pivotal Study FRESH

Quantum Genomics Appoints Sarah Merlen Boulenger as Head of Regulatory Affairs

Consensus forecasts updated

No independent directors

Quantum Genomics Announces Publication of a New Scientific Article Featuring QGC606

Quantum Genomics Announces Granting of New Patents Protecting QGC606

Quantum Genomics Société Anonyme announced that it expects to receive $2 million in funding from Gulf Pharmaceutical Industries P.S.C.

No longer forecast to breakeven

Quantum Genomics Presents Results from Phase IIb QUORUM Study of Firibastat

Quantum Genomics Société Anonyme announced that it has received €0.87 million in funding from Orient EuroPharma Co., Ltd.

Quantum Genomics Launches Phase III Pivotal REFRESH Study in Difficult-to-treat/Resistant Hypertension with Once-a-day Formulation of Firibastat

New 90-day high: €5.54

Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Faran

Quantum Genomics Signs Strategic Contract with Delpharm

Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with DongWha Pharm

New 90-day high: €4.07

Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Xediton Pharmaceuticals

Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Qilu Pharmaceutical to Develop and Commercialize Firibastat in Greater China Region, Hong Kong and Macao

New 90-day high: €3.14

Analysts update estimates

Quantum Genomics Société Anonyme Announces Resignation of Jean-Paul Kress from the Board

Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Orient EuroPharma (OEP)

New 90-day low: €2.28

New 90-day low - €2.51

CEO

Görev süresi

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi